United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l) - isoniazid 100 mg - isoniazid is recommended for all forms of tuberculos in which organisms are susceptible. however, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. single-drug treatment of active tuberculos with isoniazid, or any other medication, is inadequate therapy. isoniazid is recommended as preventive therapy for the following groups, regardless of age. (note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): 1. persons with human immunodeficiency virus (hiv) infection (≥ 5 mm) and persons with risk factors for hiv infection whose hiv infection status is unknown but who are suspected of having hiv infection. preventive therapy may be considered for hiv infected persons who are tuberculin- negative but belong to groups in which the prevalence of tuberculosis infection is high. candidates for preventive therapy who have hiv infection should have a minimum of 12

United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l) - isoniazid 50 mg in 5 ml - isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. however, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. isoniazid is recommended as preventive therapy for the following groups, regardless of age. (note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): - persons with human immunodeficiency virus (hiv) infection (≥ 5 mm) and persons with risk factors for hiv infection whose hiv infection status is unknown but who are suspected of having hiv infection. preventive therapy may be considered for hiv infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. candidates for preventive therapy who have hiv infection should have a minimum of 1

United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - prednisone (unii: vb0r961hzt) (prednisone - unii:vb0r961hzt) - prednisone 2.5 mg - prednisone tablets are indicated in the following conditions: - endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer - rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acu

United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - albendazole (unii: f4216019ln) (albendazole - unii:f4216019ln) - albendazole 200 mg - albenza is indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, taenia solium . albenza is indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, echinococcus granulosus . albenza is contraindicated in patients with known hypersensitivity to the benzimidazole class of compounds or any components of albenza. pregnancy category c. there are no adequate and well-controlled studies of albenza administration in pregnant women. albenza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. albenza should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. obtain pregnancy test prior to prescribing albenza to women of reproductive potential. advise women of reproductive potential to use effective birth control for the duration of albenza therapy and for

United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - artemether (unii: c7d6t3h22j) (artemether - unii:c7d6t3h22j) - artemether 20 mg

United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin extended-release tablets, usp and other antibacterial drugs, clarithromycin extended-release tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clarithromycin extended-release tablets, usp are indicated for the treatment of adults with mild to moderate infection caused by susceptible strains of the designated microorganisms in the conditions listed below: acute maxillary sinusitis due to haemophilus influenzae, moraxella catarrhalis , or streptococcus pneumoniae. acute bacterial exacerbation of chronic bronchitis due to

United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 800 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella  species, enterobacter  species, morganella morganii , proteus mirabilis  and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a sing

United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d) - ivermectin 3 mg - stromectol is indicated for the treatment of the following infections: strongyloidiasis of the intestinal tract . stromectol is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite strongyloides stercoralis . this indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (see clinical pharmacology, clinical studies.) onchocerciasis . stromectol is indicated for the treatment of onchocerciasis due to the nematode parasite onchocerca volvulus . this indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of west africa. the comparative studies used diethylcarbamazine citrate (dec-c). note: stromectol has no activity against adult onchocerca volvulus parasites. the adult parasites resid

United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - rifabutin (unii: 1w306tda6s) (rifabutin - unii:1w306tda6s) - rifabutin 150 mg - mycobutin capsules are indicated for the prevention of disseminated mycobacterium avium complex (mac) disease in patients with advanced hiv infection. mycobutin capsules are contraindicated in patients who have had clinically significant hypersensitivity to rifabutin or to any other rifamycins.

United States - English - NLM (National Library of Medicine)

department of state health services, pharmacy branch - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 100 mg in 5 ml - zyvox is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. zyvox is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [ see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [ see clinical studies (14) ]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [ see clinical studies (14) ]. complicated skin and skin structure infections, including diabetic foot infections, without